AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04158271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube Leackage
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
Study NCT03655665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin otic solution
Description: Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
Study NCT04055610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training using H-MEX exoskeleton
Description: Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
Study NCT04296045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCE
Description: Ingestion of 15g MCE in water after min 10 hours of fasting
Study NCT04296045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Ingestion of 15g glucose in water after min 10 hours of fasting
Study NCT04296045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Ingestion of 15g glucose in water after min 10 hours of fasting
Study NCT01640171 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Xylocaine 2% Injectable Anesthetic
Description: xylocaine 2% injection 0.1 cc
Study NCT01640171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Proparacaine Hydrochloride 0.5% Drop
Description: Topical drop given first to the treated eye.
Study NCT01640171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tetravisc 0.5% Gel
Description: Gel applied to eye 3 times prior to treatment
Study NCT01640171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acuvail
Description: Anti-inflammatory drop given after treatment
Study NCT01640171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intra-vitreal Anti-VEGF Drug
Description: Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
Study NCT00796393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033
Description: 1 pill per day for 12 weeks
Study NCT00796393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch of potato
Description: 1 pill per day for 12 weeks
Study NCT04394312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent PLAYSHOP
Description: The Parent PLAYSHOP includes:~1. Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~2. Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~3. Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support.
Study NCT03297398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group-1 (15mg, OPK-88004)
Description: 15mg, OPK-88004
Study NCT03297398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group-2 (25 mg,OPK-88004)
Description: 25 mg,OPK-88004
Study NCT03297398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03137706 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo fresh tumor tissue collection
Study NCT03137706 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03137706 — intervention group
Intervention type: OTHER
Intervention: Laboratory Procedure
Description: Tissue stiffness and cell viability analysis
Study NCT01728623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080 capsule
Description: E7080 is administered as continuous once daily dosing in an uncontrolled manner
Study NCT02957695 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Neurofeedback
Description: The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
Study NCT02957695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-Neurofeedback
Description: The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH.
Study NCT03443414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 suspension
Description: A dual PDE3/PDE 4 inhibitor
Study NCT03443414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study NCT00887029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuoTrav (travoprost-timolol ophthalmic drops)
Description: topical ophthalmic drops instilled 1 drop daily
Study NCT00887029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalacom (latanoprost-timolol ophthalmic drops)
Description: topical ophthalmic drops instilled 1 drop daily
Study NCT02676609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated carbohydrate and meal insulin dose computing
Description: Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
Study NCT03499262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Social ABCs
Description: Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: yellow film-coated 100 mg. tablets
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Narlaprevir
Description: yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ritonavir
Description: 100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
Description: 180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
Description: 180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight >105 kg) mg/day with Peginterferon alfa-2b
Study NCT03833362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight >105 kg) mg/day with Peginterferon alfa-2b
Study NCT03867968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Traumatic Brain Injury website for family members.
Study NCT01351948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
Study NCT01351948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
Description: 5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
Study NCT01351948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + AMA1-C1/Alhydrogel®
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
Study NCT01351948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
Study NCT01351948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + MVA AMA1
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections
Study NCT05003830 — intervention group
Intervention type: DEVICE
Intervention: PET/MR
Description: 18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
Study NCT03668522 — intervention group
Intervention type: OTHER
Intervention: Genetic testing
Description: To determine whether H3F3AK27M exist in spinal glioma
Study NCT01584505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 + CHF5992 dose 1 BID
Description: CHF1535 + CHF5992 dose 1 BID for 14 days
Study NCT01584505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 + CHF5992 dose2 BID
Description: CHF1535 + CHF5992 dose 2 BID for 14 days
Study NCT01584505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF1535 daily dose
Description: CHF1535 daily dose for 14 days
Study NCT01841801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Adhesive Patch
Study NCT01841801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Thermal Adhesive Patch
Study NCT01841801 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Study NCT03439410 — intervention group
Intervention type: OTHER
Intervention: Clinical Complexity Index
Description: Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
Study NCT00441987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI-953
Study NCT03890978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: promotional Exclusive breastfeeding text messages
Description: promotional Exclusive breastfeeding text messages will be send to women via mobile phone
Study NCT03890978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: promotional Exclusive breastfeeding text messages
Description: promotional Exclusive breastfeeding text messages will be send to women via mobile phone
Study NCT01512433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ture acupuncture
Description: Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
Study NCT01512433 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling.
Study NCT04857853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Without Rest Break
Description: Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks.
Study NCT04857853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise With Rest Break
Description: Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks.
Study NCT04857853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest Break
Description: Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises.
Study NCT03793959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic Supplement
Study NCT03793959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01099579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir powder
Description: Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Study NCT01099579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution
Description: Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Study NCT01099579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir capsules
Description: Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Study NCT01099579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsules
Description: Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
Study NCT04543812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Description: Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Study NCT04543812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Study NCT03153813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsaicin 8% patches (Qutenza)
Study NCT03153813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patches
Study NCT03040245 — intervention group
Intervention type: BEHAVIORAL
Intervention: Whiplash book
Study NCT03715868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-milked derived protein source formula diet
Description: Formula diet based on a non-milked derived protein source
Study NCT01062269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: Cholestyramine 4 grams one time dose
Study NCT01062269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: Cholestyramine 12 grams one dose, one day
Study NCT01062269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tang
Description: Tang one dose one day
Study NCT04606147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block
Description: The block is performed with full aseptic precautions.in lateral position \&arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
Study NCT04606147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
Study NCT01266161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg ER
Description: One 600 mg caplet dosed at 0, 12, 24 and 36 hours
Study NCT01266161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo caplet dosed at times 0, 12, 24 and 36 hours
Study NCT04592081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: Dextenza 0.4Mg Ophthalmic Insert
Study NCT04592081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: Dextenza 0.4Mg Ophthalmic Insert
Study NCT02775305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frail
Description: Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques.
Study NCT00915577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 30mcg, IM once-a-week
Study NCT00915577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use autoinjector
Description: Single-use autoinjector with Avonex 30mcg pre-filled syringe
Study NCT01390142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Deflated blood pressure cuff placed on upper arm for 30min